Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A De Groote

Showing results (31-40 of 33) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 33 results.
Frontiers in Microbiology|October 9, 2018
Optimization and Lead Selection of Benzothiazole Amide Analogs Toward a Novel Antimycobacterial AgentMary A De Groote, Thale C Jarvis, Christina Wong, et al.
The Lancet. Infectious Diseases|January 25, 2026
Safety and efficacy of CRS3123 in adults with a primary episode or first recurrence of Clostridioides difficile infection: a phase 2, randomised, double-blind, multicentre, vancomycin-controlled studyThomas Louie, Wendy Ribble, Louis Boccumini, et al.
Tuberculosis (Edinburgh, Scotland)|December 5, 2022
Microbiological profile, preclinical pharmacokinetics and efficacy of CRS0393, a novel antimycobacterial agent targeting MmpL3Urs A Ochsner, Mary A De Groote, Thale C Jarvis, et al.
Pageof 4

Showing results (31-40 of 33) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 33 results.
Frontiers in Microbiology|October 9, 2018
Optimization and Lead Selection of Benzothiazole Amide Analogs Toward a Novel Antimycobacterial AgentMary A De Groote, Thale C Jarvis, Christina Wong, et al.
The Lancet. Infectious Diseases|January 25, 2026
Safety and efficacy of CRS3123 in adults with a primary episode or first recurrence of Clostridioides difficile infection: a phase 2, randomised, double-blind, multicentre, vancomycin-controlled studyThomas Louie, Wendy Ribble, Louis Boccumini, et al.
Tuberculosis (Edinburgh, Scotland)|December 5, 2022
Microbiological profile, preclinical pharmacokinetics and efficacy of CRS0393, a novel antimycobacterial agent targeting MmpL3Urs A Ochsner, Mary A De Groote, Thale C Jarvis, et al.
Pageof 4